| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42000020 | EBV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS42000021 | EBV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS10032691 | HBV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS20002754 | HPV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS20010565 | HPV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS20011236 | HPV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS20048401 | HPV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS20048060 | HPV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS20047883 | HPV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS20047818 | HPV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PTGFR |
|---|---|
| DrugBank ID | DB00287 |
| Drug Name | Travoprost |
| Target ID | BE0000610 |
| UniProt ID | P43088 |
| Regulation Type | agonist |
| PubMed IDs | 16249494; 16505027; 18452763; 19697832; 19929706; 9038626; 19038618; 18983226; 12083996; 14733708; 12669109 |
| Citations | Ota T, Aihara M, Narumiya S, Araie M: The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63.@@Thieme H, Schimmat C, Munzer G, Boxberger M, Fromm M, Pfeiffer N, Rosenthal R: Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):938-45.@@Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002.@@Neacsu AM: [Receptors involved in the mechanism of action of topical prostaglandines]. Oftalmologia. 2009;53(2):3-7.@@Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. doi: 10.1517/14656560903300129.@@Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9.@@Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. doi: 10.1016/j.survophthal.2008.08.010.@@Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. doi: 10.1517/14740330802465474 .@@Whitson JT: Travoprost--a new prostaglandin analogue for the treatment of glaucoma. Expert Opin Pharmacother. 2002 Jul;3(7):965-77. doi: 10.1517/14656566.3.7.965.@@Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX: Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15.@@Al-Jazzaf AM, DeSantis L, Netland PA: Travoprost: a potent ocular hypotensive agent. Drugs Today (Barc). 2003 Jan;39(1):61-74. doi: 10.1358/dot.2003.39.1.799432. |
| Groups | Approved |
| Direct Classification | Prostaglandins and related compounds |
| SMILES | CC(C)OC(=O)CCCC=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1C=C[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F |
| Pathways | |
| PharmGKB | PA164781371 |
| ChEMBL | CHEMBL1200799 |
